Prodigiozan

A polysaccharide extracted from Serratia marcescens and other bacteria. It activates enzymatic activity of macrophages and stimulates phagocytic processes.

Also Known As:

Networked: 122 relevant articles (5 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Dushkin, M I: 1 article (03/2002)
2.	Shvarts, Ia Sh: 1 article (03/2002)
3.	Zubakhin, A A: 1 article (03/2002)
4.	Kuznetsov, P O: 1 article (03/2002)
5.	Safina, A F: 1 article (03/2002)
6.	Tsyrendorzhiev, D D: 1 article (03/2002)
7.	Shaban, Zh G: 1 article (09/2001)
8.	Kartel', A I: 1 article (09/2001)
9.	Titov, L P: 1 article (09/2001)

Related Diseases

1.	Tuberculosis (Tuberculoses) 01/01/1990 - "The efficacy of the antibacterial treatment of children with different forms of intrathoracic tuberculosis supplemented by prodigiosan as well as that of prodigiosan alone were analysed by means of clinical, X-ray, laboratory and immunologic methods. " 01/01/1990 - "The data of this study permit one to recommend prodigiosan as an effective non-specific impact method in the combined treatment of tuberculosis in children." 01/01/1990 - "[The results of antibacterial therapy combined with prodigiozan in children with tuberculosis]."
2.	Human Influenza (Influenza) 01/01/1990 - "[The use of prodigiozan for the nonspecific prevention of influenza and ARD among frequently ill schoolchildren]." 02/01/1969 - "[On prevention of influenza with prodigiozan]." 05/01/1969 - "[Prevention of influenza by stimulators of interferon formation, UV-virus and prodigiozan]." 02/01/1978 - "The epidemiological efficacy of 0.02 per cent solution of prodigiosan, a bacterial polysaccharide was used for the treatment of children in an area with acute respiratory infections, such as influenza and parainfluenza. "
3.	Respiratory Tract Infections (Respiratory Tract Infection) 07/01/1980 - "The data are indicative of the validity of prodigiozan in treatment of children with acute respiratory infections." 02/01/1978 - "The epidemiological efficacy of 0.02 per cent solution of prodigiosan, a bacterial polysaccharide was used for the treatment of children in an area with acute respiratory infections, such as influenza and parainfluenza. " 07/01/1980 - "The use of prodigiozan in treatment of children with acute viral respiratory infections promoted a decrease in the frequency of complications, such as pneumonia and otitis. "
4.	Inflammation 03/01/1967 - "[Effect of prodigiozan and its combination with antibiotics on the course and outcome of the acute experimental purulent inflammation]." 05/01/1985 - "It was noted that the use of methyluracil and prodigiosan in the combined treatment of erysipelas promoted an increase in the efficacy of the antibiotic therapy owing to acceleration of the local inflammation regression and the favourable effect of the treatment on the cell immunity."
5.	Erysipelas 08/01/1984 - "[Effectiveness of prodigiozan in the complex treatment of erysipelas]." 05/01/1985 - "[Possibility of increasing the efficacy of antibiotic therapy of erysipelas using combinations of methyluracil with prodigiozan]." 05/01/1985 - "It was noted that the use of methyluracil and prodigiosan in the combined treatment of erysipelas promoted an increase in the efficacy of the antibiotic therapy owing to acceleration of the local inflammation regression and the favourable effect of the treatment on the cell immunity."

Related Drugs and Biologics

1.	Levamisole (Decaris)
2.	6-methyluracil
3.	thymopoietin III
4.	sodium nucleinate
5.	Anti-Bacterial Agents (Antibiotics)
6.	Muramidase (Lysozyme)
7.	Cyclophosphamide (Cytoxan)
8.	Zymosan
9.	Prednisolone (Predate)
10.	Ibuprofen (Motrin)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Intravenous Injections
3.	Drug Therapy (Chemotherapy)
4.	Aftercare (After-Treatment)